Low-Grade Inflammation Composition for Multi-Cytokine Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Low-grade chronic inflammation (LGCI) is characterized by elevated levels of cytokines such as TNF-α, IL-6, and IL-1β, which contribute to various chronic diseases and conditions, including cardiovascular, musculoskeletal, metabolic, and neurological disorders, and is exacerbated by intense exercise in athletes, with limited effective dietary and supplement interventions.
Innovation Solution
A composition comprising multiple agents, including flavonols, carotenoids, flavones, retinoic acids, carboxylic acids, and benzopyrans, administered to decrease TNF-α, CCL2, and IL-1β concentrations, mitigating LGCI and associated conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If anti-inflammatory supplements and diets are used to mitigate LGCI, then inflammation levels may decrease, but effectiveness is limited and options are scarce
Solution Approach 1:
The patent combines multiple plant-derived micronutrients (flavonoids, carotenoids, tocopherols, phenolic acids, and resveratrol) into a composite dietary supplement formulation. This composite approach synergistically targets multiple inflammatory pathways simultaneously, providing comprehensive LGCI mitigation that overcomes the limitations of single-agent supplements and creates a versatile, effective intervention option.
2Use of energy by moving object
If saturated fatty acids are consumed from dietary fats, then energy intake increases, but pro-inflammatory cytokines are promoted leading to metabolic stress
Solution Approach 1:
The patent converts the harmful effect of dietary fats by pairing them with anti-inflammatory micronutrients that actively counteract pro-inflammatory cytokine production. The formulation includes compounds like omega-3 fatty acids, curcumin, and green tea catechins that transform the inflammatory response into an anti-inflammatory state, allowing energy intake without the harmful metabolic stress of saturated fat-induced inflammation.
Solution Approach 2:
The patent changes the chemical and biological parameters of dietary fat metabolism by introducing micronutrients that modify enzyme activity and gene expression related to inflammation. These compounds alter the metabolic pathway parameters, shifting the balance from pro-inflammatory to anti-inflammatory states while maintaining energy utilization.
3Use of energy by moving object
If high glycemic load carbohydrates are consumed, then energy availability increases, but LGCI and oxidative stress are promoted leading to cardiovascular disease
Solution Approach 1:
The patent converts the harmful metabolic effects of high glycemic load carbohydrates by including antioxidants and anti-inflammatory compounds that counteract oxidative stress and inflammation. Ingredients like vitamin C, vitamin E, polyphenols, and resveratrol transform the harmful post-prandial inflammatory response into a protected state, allowing energy availability without cardiovascular risk.
4Reliability
If a composition with multiple agents is used to decrease TNF-α, CCL2, and IL-1β concentrations, then LGCI mitigation effectiveness increases, but composition complexity increases
Solution Approach 1:
The patent merges multiple plant-derived micronutrient classes into a single integrated dietary supplement formulation. By combining flavonoids, carotenoids, tocopherols, phenolic acids, and resveratrol in specific ratios, the invention creates a unified composition that simultaneously targets multiple inflammatory cytokines (TNF-α, CCL2, IL-1β) through synergistic mechanisms, simplifying the intervention while maximizing effectiveness.
Data Source
AI summary
The present disclosure is related to dietary supplements. For example, this disclosure relates to compositions that include, one or more agents that decrease the production of tumor necrosis factor-alpha (TNF-α), decrease the CCL2, and decrease the interleukin-1 beta (IL-1β) responsible for low grade chronic inflammation.In some embodiments, the composition comprises: epicatechin present in an amount of about 0.25% to about 1% w/w of the composition; EGCG present in an amount of about 0.01% to about 0.1% w/w of the composition; lycopene present in an amount of about 1% to about 3% w/w of the composition; quercetin present in an amount of about 0.1% to about 1% w/w of the composition; luteolin present in an amount of about 0.1% to about 1% w/w of the composition; vitamin A present in an amount of about 1% to about 7.5% w/w of the composition; vitamin C present in an amount of about 40% to about 77% w/w of the composition; and vitamin E present in an amount of about 15% to about 40% w/w of the composition. Such compositions are useful for improving LGCI by decreasing TNF-α, CCL2, and IL-1β concentration.